

ESTTA Tracking number: **ESTTA1324807**
Filing date: **11/28/2023**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD

Applicants	EyePoint Pharmaceuticals US, Inc.
Application serial no.	97724740
Application filing date	12/20/2022
Mark	DURAVU
Date of publication	10/31/2023
Potential opposer's Correspondence information	MAURY M. TEPPER, III TEPPER & EYSTER, PLLC 3724 BENSON DRIVE RALEIGH, NC 27609 UNITED STATES Primary email: mtepper@teiplaw.com Secondary email(s): athompson@teiplaw.com 9198618903

First 30 Day Request for Extension of Time to Oppose

Pursuant to 37 C.F.R. Section 2.102, Novartis AG, CH-4002, Basel, 4002, SWITZERLAND, a corporation organized under the laws of Switzerland, respectfully requests that it be granted a 30-day extension of time to file a notice of opposition against the above-identified mark.

The time within which to file a notice of opposition is set to expire on 11/30/2023. Novartis AG respectfully requests that the time period within which to file an opposition be extended until 12/30/2023.

Respectfully submitted,
/Maury M. Tepper, III/
Tepper III, Maury M
mtepper@teiplaw.com
11/28/2023